Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of July 12- 18, 2021.
He highlights the KEYNOTE-522 trial where the addition of pembrolizumab to neoadjuvant chemotherapy has shown an EFS benefit in patients with early triple-negative breast cancer.
Alerts this week cover papers from The Breast, Lancet Oncology and Gut.
You can watch Dr Morgan's previous roundup here.
Follow Dr Morgan on twitter: @OncoAlert
Follow ecancer on twitter: @ecancer